TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00775411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 700 µg dexamethasone intravitreal injection at Day 1 in the study eye.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
Study: NCT02361086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28 day cycles
Description: VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
Study: NCT01111253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days.
Study: NCT04652388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional counseling about mediterranean diet
Study: NCT00663585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vipassana Meditation
Description: 12 day retreat where participants learn to meditate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vipassana Meditation
Description: 12 day retreat where participants learn to meditate
Study: NCT03306173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercially available cigarette
Description: Commercially available cigarette with either \~0% or \~25% filter ventilation. Menthol flavor will be available in both types.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercially available cigarette
Description: Commercially available cigarette with either \~0% or \~25% filter ventilation. Menthol flavor will be available in both types.
Study: NCT01702857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffered saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 µg TDENV-PIV with Alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 µg TDENV-PIV with AS01E adjuvant
Study: NCT02450812

Intervention type: DRUG
Intervention: Radium-223-dichloride (Xofigo, BAY88-8223)
Description: according to Summary of Product Characteristics
Study: NCT03603639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2730-matched placebo capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2730-matched placebo capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2730-matched placebo capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2730-matched placebo capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2730-matched placebo capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive E2730-matched placebo capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: Participants will receive E2730 capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: Participants will receive E2730 capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: Participants will receive E2730 capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: Participants will receive E2730 capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: Participants will receive E2730 capsule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: Participants will receive E2730 capsule, orally.
Study: NCT01896180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-1101
Description: ALZ-1101 Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost 0.005% Ophthalmic Solution
Study: NCT02934204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT03782571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 3
Description: 1-DAY ACUVUE® MOIST MULTIFOCAL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 3
Description: 1-DAY ACUVUE® MOIST MULTIFOCAL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 3
Description: 1-DAY ACUVUE® MOIST MULTIFOCAL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 3
Description: 1-DAY ACUVUE® MOIST MULTIFOCAL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Bare Eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Bare Eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Bare Eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Bare Eye
Study: NCT00633490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
Study: NCT03782129

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Blood samples drawn during hospitalisations when needed

Intervention type: OTHER
Intervention: Clinical exam and DFU medical cares
Description: Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
Study: NCT01270360

Intervention type: DEVICE
Intervention: COLOHYBRITEST OR VALIHYBRITEST
Description: Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
Study: NCT01435148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation, implanted
Description: Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation, implanted
Description: Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
Study: NCT04671056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: MGL-3196 100 mg tablet administered orally in the morning for 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
Study: NCT03328442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA Technique
Description: VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified coronally advanced flap
Description: modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
Study: NCT03941028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed titanium implant
Description: The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed titanium implant
Description: The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed titanium implant
Description: The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
Study: NCT03295032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility.
Study: NCT01756339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match solithromycin
Study: NCT04078854

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes education
Description: Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
Study: NCT05950165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHO-H01
Description: Phase 1:~Subjects will be administered intravenous (IV) infusion of assigned dose level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 21-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHO-H01 at RP2D
Description: Subjects will be administered intravenous (IV) infusion of RP2D level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 28-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will receive oral lenalidomide 20 mg once daily from Day 1 to Day 21 per 28-day cycle.
Study: NCT00582426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Long Acting Release
Description: Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
Study: NCT02824211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right Dose System
Description: Automated titration of oxygen system during exertion
Study: NCT03200652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic availability of lysine in wheat
Description: Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
Study: NCT04267068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset and Modifiable Risk Factor Information
Description: 15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
Study: NCT02522988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-label placebo intervention
Description: An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-label placebo intervention
Description: An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
Study: NCT01667809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to work
Description: Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
Study: NCT02045290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04988776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m
Description: patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block
Description: Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
Study: NCT01776359

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Protein
Description: 2.4g/kg of protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Protein
Description: 1.2g/kg of protein
Study: NCT03683550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNE with preoperative hybrid SPECT/CT
Description: Single-photon emission computed tomography/computed tomography (SPECT/CT) provides complementary functional and anatomical information and has been shown to be superior to planar imaging in a number of indications. It can provide valuable information before sentinel lymph node biopsy and advocate its use in a range of tumors such as truncal and head and neck melanomas.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard SLNE
Description: The current gold standard for detection and targeted extirpation of the sentinel lymph node (SLN) is preoperative lymphoscintigraphy.~Lymphoscintigraphy (sentinel lymph node mapping) is an imaging technique used to identify the lymph drainage basin, determine the number of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel node in an unexpected location, and mark the sentinel node over the skin for biopsy.
Study: NCT00992992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab followed by CHOP
Description: Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
Study: NCT03452683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movn Mobile App
Description: Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
Study: NCT00328445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Action
Description: See publications
Study: NCT01804010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine and placebo
Description: Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivabradine and placebo
Description: Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
Study: NCT00759642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib 1500 mg PO daily
Study: NCT01662856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols
Description: Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Compression
Description: Direct manual compression of target bleeding site with gauze/laparotomy pads.
Study: NCT00759655

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Moroctocog alfa
Description: Patients will receive Moroctocog alfa according to their investigator's prescription.
Study: NCT02080208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow
Description: patients receive oxygen via high flow oxygen therapy during 20 minutes
Study: NCT01467193

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fat diet
Description: Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.

Intervention type: OTHER
Intervention: 2h standardized aerobic exercise
Description: Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours